Chao Wan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chao Wan has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Yajie Sun
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
24 shared publications - Jingshu Meng
Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China
22 shared publications - Fang Huang
Huazhong University of Science and Technology 1 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
19 shared publications - Wenwen Wei
Huazhong University of Science and Technology 1 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
19 shared publications - Xiao Yang
Huazhong University of Science and Technology 1 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
19 shared publications - Yue Deng
Huazhong University of Science and Technology 1 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
19 shared publications
Latest Publications
- 10 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Response-Adapted Surgery after Neoadjuvant Immunochemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH): A Single-Arm Phase II Trial
Purpose: We assessed the feasibility and efficacy of a response-adapted surgical strategy in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) achieving major tumor regression after neoadjuvant immunochemotherapy (NAICT). Patients and Methods: This phase II, single-arm, prospective trial enrolled patients with resectable, human papillomavirus–negative stage III to IVA LA-HNSCC. All received three cycles of NAICT (penpulimab, nab-paclitaxel, and cisplatin). Pre–cycle 3 imaging and laryngoscopy guided surgery: Patients with ≥50% primary tumor regression underwent reduced-volume surgery (RVS); those with <50% regression received standard-volume surgery (SVS). All received risk-adapted adjuvant radiotherapy. The primary endpoint was 2-year disease-free survival (DFS). Results: Fifty patients completed NAICT, with an objective response rate of 94% [95% confidence interval (CI), 84%–99%]. At a median follow-up of 34.0 months (IQR, 30.1–39.5), the 2-year DFS for the per-protocol cohort was 83% (95% CI, 69%–91%). The RVS group (n = 42) achieved a 2-year DFS of 90% (95% CI, 77%–96%) with 100% laryngeal preservation in laryngeal/hypopharyngeal cancers, whereas the SVS group (n = 5) had a 2-year DFS of 20% (95% CI, 0.8%–58%). Grade 3 adverse events (AE) occurred in 16% of patients related to NAICT and in 15% related to surgery; there were no grade 4 or 5 AEs. At 9 months after radiotherapy, most quality-of-life scores improved or stabilized compared with baseline. Conclusions: The REMATCH trial provides the first prospective evidence that a response-adapted surgical strategy after NAICT is feasible. Patients achieving ≥50% primary tumor regression derived promising survival and universal laryngeal preservation. These findings support the initiation of phase III randomized trials to validate this de-escalation strategy.
- 10 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Response-Adapted Surgery after Neoadjuvant Immunochemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH): A Single-Arm Phase II Trial
Purpose: We assessed the feasibility and efficacy of a response-adapted surgical strategy in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) achieving major tumor regression after neoadjuvant immunochemotherapy (NAICT). Patients and Methods: This phase II, single-arm, prospective trial enrolled patients with resectable, human papillomavirus–negative stage III to IVA LA-HNSCC. All received three cycles of NAICT (penpulimab, nab-paclitaxel, and cisplatin). Pre–cycle 3 imaging and laryngoscopy guided surgery: Patients with ≥50% primary tumor regression underwent reduced-volume surgery (RVS); those with <50% regression received standard-volume surgery (SVS). All received risk-adapted adjuvant radiotherapy. The primary endpoint was 2-year disease-free survival (DFS). Results: Fifty patients completed NAICT, with an objective response rate of 94% [95% confidence interval (CI), 84%–99%]. At a median follow-up of 34.0 months (IQR, 30.1–39.5), the 2-year DFS for the per-protocol cohort was 83% (95% CI, 69%–91%). The RVS group (n = 42) achieved a 2-year DFS of 90% (95% CI, 77%–96%) with 100% laryngeal preservation in laryngeal/hypopharyngeal cancers, whereas the SVS group (n = 5) had a 2-year DFS of 20% (95% CI, 0.8%–58%). Grade 3 adverse events (AE) occurred in 16% of patients related to NAICT and in 15% related to surgery; there were no grade 4 or 5 AEs. At 9 months after radiotherapy, most quality-of-life scores improved or stabilized compared with baseline. Conclusions: The REMATCH trial provides the first prospective evidence that a response-adapted surgical strategy after NAICT is feasible. Patients achieving ≥50% primary tumor regression derived promising survival and universal laryngeal preservation. These findings support the initiation of phase III randomized trials to validate this de-escalation strategy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1-S5 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Table S1 presents the sequences of primers used for RT-qPCR analysis. Table S2 lists the sequences of primers used for ChIP-PCR. Table S3 contains the differentially expressed metabolites identified in tumor tissues of Lewis tumor-bearing mice treated with IgG2 (Ctrl) or anti-PD-1 monoclonal antibody. Table S4 summarizes the differentially expressed genes in untreated and IFN-γ-treated bone marrow-derived macrophages (BMDMs). Table S5 provides the differentially expressed genes in bone marrow-derived dendritic cells (BMDCs) under IFN-γ versus IFN-γ + 4-OI treatment conditions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1-S5 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Table S1 presents the sequences of primers used for RT-qPCR analysis. Table S2 lists the sequences of primers used for ChIP-PCR. Table S3 contains the differentially expressed metabolites identified in tumor tissues of Lewis tumor-bearing mice treated with IgG2 (Ctrl) or anti-PD-1 monoclonal antibody. Table S4 summarizes the differentially expressed genes in untreated and IFN-γ-treated bone marrow-derived macrophages (BMDMs). Table S5 provides the differentially expressed genes in bone marrow-derived dendritic cells (BMDCs) under IFN-γ versus IFN-γ + 4-OI treatment conditions.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1-S10 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Figure S1 shows the metabolic alterations induced by anti-PD-1 treatment in mice. Figure S2 presents the effects of itaconate on anti-PD-1 therapy in vivo. Figure S3 shows the impact of Acod1 deletion on the tumor immune microenvironment. Figure S4 presents the oxidative stress levels in DCs and TAMs within the tumor immune microenvironment. Figure S5 shows the efficiency of immune cell depletion in vivo. Figure S6 demonstrates that the impact of Acod1 deletion on anti-PD-1 therapy is dependent on CD8+ T cells. Figure S7 presents ACOD1 expression patterns in the tumor immune microenvironment. t-SNE projections and violin plots illustrate ACOD1 expression across myeloid and immune cell clusters in lung adenocarcinoma samples. Figure S8 shows the transcriptional regulation of Acod1 via the IFN-γ-JAK/STAT1 axis. Figure S9 presents the inhibitory effects of itaconate on DC antigen cross-presentation. Figure S10 shows the effects of itaconate on DC metabolism and signaling pathways.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S10 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Figure S1 shows the metabolic alterations induced by anti-PD-1 treatment in mice. Figure S2 presents the effects of itaconate on anti-PD-1 therapy in vivo. Figure S3 shows the impact of Acod1 deletion on the tumor immune microenvironment. Figure S4 presents the oxidative stress levels in DCs and TAMs within the tumor immune microenvironment. Figure S5 shows the efficiency of immune cell depletion in vivo. Figure S6 demonstrates that the impact of Acod1 deletion on anti-PD-1 therapy is dependent on CD8+ T cells. Figure S7 presents ACOD1 expression patterns in the tumor immune microenvironment. t-SNE projections and violin plots illustrate ACOD1 expression across myeloid and immune cell clusters in lung adenocarcinoma samples. Figure S8 shows the transcriptional regulation of Acod1 via the IFN-γ-JAK/STAT1 axis. Figure S9 presents the inhibitory effects of itaconate on DC antigen cross-presentation. Figure S10 shows the effects of itaconate on DC metabolism and signaling pathways.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S11 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Targeting CD24 does not sensitize radiotherapy in vitro.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S11 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Targeting CD24 does not sensitize radiotherapy in vitro.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S13 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Validation of the immune cell depletion efficiency, related to Fig. 7.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S13 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Validation of the immune cell depletion efficiency, related to Fig. 7.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation suppresses APC/C-mediated ubiquitination of GPAA1.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation suppresses APC/C-mediated ubiquitination of GPAA1.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation enhances GPAA1 to promote CD24 membrane trafficking.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation enhances GPAA1 to promote CD24 membrane trafficking.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S8 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation mediates GPAA1 accumulation via APC/C disruption.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S8 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation mediates GPAA1 accumulation via APC/C disruption.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S10 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
GPAA1 inhibition combined with radiation promotes macrophage uptake and abolished by CD24 overexpression.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S10 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
GPAA1 inhibition combined with radiation promotes macrophage uptake and abolished by CD24 overexpression.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S12 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
CD24-radiation combination therapy activates macrophages and T cells.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S12 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
CD24-radiation combination therapy activates macrophages and T cells.